Lindsey Smith Tallie,Barry Popkin
Lindsey Smith Tallie
GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study [0.03%]
已有糖尿病的肾移植受者的GLP-1受体激动剂治疗：一项回顾性队列研究
Babak J Orandi,Yusi Chen,Yiting Li et al.
Babak J Orandi et al.
Background: Given the cardiovascular, renal, and survival benefits of GLP-1 receptor agonists for diabetes, these agents could be effective among kidney transplant recipients. However, kidney transplant recipients are dis...
GLP-1 receptor agonists: even for kidney transplant recipients with pre-existing diabetes? [0.03%]
GLP-1受体激动剂：适用于已有糖尿病的肾移植接受者吗？
Monica Cortinovis,Norberto Perico,Giuseppe Remuzzi
Monica Cortinovis
Promising treatment options with tirzepatide for Japanese individuals with obesity disease [0.03%]
Tir扎帕肽治疗肥胖症日本患者的前景展望
Michael A Nauck,Soo Lim
Michael A Nauck
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial [0.03%]
每周一次Tirzepatide对日本肥胖疾病患者的有效性和安全性(SURMOUNT-J)：一项多中心、随机、双盲、安慰剂对照的三期试验
Takashi Kadowaki,Arihiro Kiyosue,Tomotaka Shingaki et al.
Takashi Kadowaki et al.
Background: Data on tirzepatide in Asian patients with obesity are limited. This study aimed to gain a better understanding of tirzepatide for treatment of Japanese patients with obesity disease (BMI ≥25 kg/m2 with exces...
Andreas L Birkenfeld,Michael Bergman
Andreas L Birkenfeld